Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | mTNBC: tumor mutational burden & PTEN Alterations as molecular correlates

Sara Tolaney • 14 May 2020
ESMO Breast 2020
Breast Cancer Checkpoint Inhibitors

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, discusses tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer (mTNBC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sara Tolaney

1:49
Final OS analysis of sacituzumab govitecan in TROPiCS-02
Sara Tolaney • 2 Jun 2023
1:08
ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC
Sara Tolaney • 2 Jun 2023
1:09
Where are we in sequencing ADCs in HR+ breast cancer?
Sara Tolaney • 2 Jun 2023
1:00
TROPiCS-02: sacituzumab govitecan in HR+/HER2- breast cancer
Sara Tolaney • 2 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals